Literature DB >> 89390

Tolfenamic acid is as effective as ergotamine during migraine attacks.

H Hakkarainen, H Vapaatalo, G Gothoni, J Parantainen.   

Abstract

Tolfenamic acid (a potent inhibitor of prostaglandin biosynthesis), ergotamine tartrate, acetylsalicylic acid, or placebo was administered during 160 migraine attacks in twenty women in a double-blind, cross-over study. Tolfenamic acid and ergotamine were equally effective in reducing the duration and intensity of attacks, but side-effects, especially nausea, were less common with tolfenamic acid. This probably accounted for the patients' preference for tolfenamic acid. The effectiveness of tolfenamic acid in acute migraine attacks accords with the postulated role of prostaglandins in migraine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 89390     DOI: 10.1016/s0140-6736(79)90343-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  Do non-steroidal anti-inflammatory agents have a role in the treatment of migraine headaches?

Authors:  S Diamond; F G Freitag
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 2.  The severity model of chronic headache.

Authors:  M J Smith; N M Jensen
Journal:  J Gen Intern Med       Date:  1988 Jul-Aug       Impact factor: 5.128

Review 3.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

4.  Orally administered tolfenamic acid inhibits leukotriene synthesis in isolated human peripheral polymorphonuclear leukocytes.

Authors:  E Moilanen; J Alanko; A Juhakoski; H Vapaatalo
Journal:  Agents Actions       Date:  1989-08

Review 5.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

7.  Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.

Authors:  Lina Adwan; Gehad M Subaiea; Nasser H Zawia
Journal:  Neuropharmacology       Date:  2014-01-21       Impact factor: 5.250

8.  Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates.

Authors:  R G Khalifah; C E Hignite; P J Pentikäinen; A Penttilä; P J Neuvonen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

9.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 10.  A review of the treatment of primary headaches. Part I: Migraine.

Authors:  M Leone; L Grazzi; D D'Amico; F Moschiano; G Bussone
Journal:  Ital J Neurol Sci       Date:  1995-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.